Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

By Ronald L. Hamilton. Brain Pathology, 2000

755 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Neurology, Physiology

View Paper: https://www.semanticscholar.org/paper/a1d03adff47fd7dda404814ceb7b846ff26326fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Complementary and alternative medicine

1. Rudolph E. Tanzi
2. Ian G. McKeith
3. Lars Bertram

In Neurology

1. E. Masliah
2. Rudolph E. Tanzi
3. John Q. Trojanowski
4. Ian G. McKeith
5. Lars Bertram
6. Dennis W. Dickson
7. V. Lee
8. J. Götz

In Physiology

1. Rudolph E. Tanzi
2. E. Masliah
3. Lars Bertram
4. C. Duyckaerts
5. Thomas J. Montine
6. T. Beach
7. John Q. Trojanowski
8. Ian G. McKeith

Citations in the corpus

• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop (2006, positive): “Using such sensitive methodsLewy-related pathology has also been reported as frequently present in the amygdala and periamygdaloid cortex in AD [49] calling into question yet again the significance of LB in determining clinical phenotype.”
• National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2011, neutral): “LBs are frequent in the setting of moderate-to-severe levels of AD neuropathologic change [27, 59], including some early-onset familial AD cases [32, 33].”
• National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease (2012, background): “LBs are frequent in the setting of moderate-to-severe levels of AD neuropathologic change [52,55], including some early-onset familial AD cases with APP or PSEN-1 mutations [56,57].”
• Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration (2002, methodology): “The most specific method for detecting Lewy bodies is immunostaining for a-synuclein (64, 65), and this is the method of choice to identify Lewy bodies.”
• Unified Staging System for Lewy Body Disorders: Correlation with Nigrostriatal Degeneration, Cognitive Impairment and Motor Dysfunction (2009, background): “More caudal brainstem structures are now recognized as involved prior to the SN while the amygdala and associated limbic structures may be struck first and hardest in some cases [11, 40, 63, 65, 75, 84, 85].”
• The genetic epidemiology of neurodegenerative disease. (2005, background): “However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e. odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly mor”